台灣臨床試驗主持人資料庫|TPIDB

2018-12-01 - 2024-12-31

Phase III

Completed

A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH NEOADJUVANT DOXORUBICIN + CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL + TRASTUZUMAB + PERTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER

Condition/Disease

EARLY HER2-POSITIVE BREAST CANCER
Test Drug

Atezolizumab

Participate Sites
5Sites

Terminated4Sites

王惠暢

China Medical University Hospital

Division of General Surgery

2020-09-01 - 2021-05-31

Phase I

A phase I, open-label study to evaluate the safety, tolerability, and immunogenicity of UB-612 vaccine in healthy adult volunteers

Condition/Disease

Prevent COVID-19 infection
Test Drug

UB-612

Participate Sites
1Sites

Study ended1Sites

黃高彬

China Medical University Hospital

Division of Infectious Disease

2013-09-01 - 2019-03-08

Phase III

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Condition/Disease

Diffuse Large B-Cell Lymphoma(DLBCL)
Test Drug

Ibrutinib

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

葉士芃

China Medical University Hospital

Division of Hematology & Oncology

2014-05-01 - 2020-12-31

Phase III

A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)

Condition/Disease

Rheumatoid Arthritis
Test Drug

CNTO136 (sirukumab)

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

藍忠亮

China Medical University Hospital

2017-01-15 - 2020-02-28

Phase II

An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type

Condition/Disease

Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type
Test Drug

Daratumumab

Participate Sites
4Sites

Terminated2Sites

Study ended1Sites

葉士芃

China Medical University Hospital

Division of Hematology & Oncology

2013-10-01 - 2017-12-31

Phase III

An Open-Label Two-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects with Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment with Available Anti-Parkinsonian Medications

Condition/Disease

Available Anti-Parkinsonian Medications
Test Drug

ABT-SLV187 (Duodopa)

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

蔡崇豪

China Medical University Hospital

Division of Neurology

2015-10-20 - 2017-05-30

Phase III

A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults with Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)

Condition/Disease

Chronic Hepatitis C Virus Genotype 2 Infection
Test Drug

ABT-493/ABT-530

Participate Sites
7Sites

Terminated4Sites

Study ended1Sites

彭成元

China Medical University Hospital

Digestive System Department

彭成元

China Medical University Hospital-Taipei

未分科

2012-07-01 - 2015-07-31

Phase I

A Multicenter, Phase 1/1b Open-Label, Dose-Escalation Study of ABT-700, a Monoclonal Antibody, in Subjects with Advanced Solid Tumor

Condition/Disease

Advance solid tumor/non-small cell lung cancer/astric/gastroesophageal junction adenocarcinoma
Test Drug

ABT-700

Participate Sites
3Sites

Terminated3Sites

夏德椿

China Medical University Hospital

Division of Thoracic Medicine

2013-05-28 - 2016-09-21

Phase III

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects with Systemic Lupus Erythematosus

Condition/Disease

Systemic Lupus Erythematosus
Test Drug

Blisibimod

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

黃春明

China Medical University Hospital

2013-08-22 - 2015-06-30

Phase III

A randomized, double-blind, double-dummy, parallel group, international multicenter study assessing the efficacy and safety of a netupitant-palonosetron Fixed Dose Combination (FDC) compared to an extemporary combination of granisetron and aprepitant on the prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with cancer.

Condition/Disease

nausea and vomiting
Test Drug

netupitant-palonosetron Fixed Dose Combination (FDC)

Participate Sites
7Sites

Terminated7Sites

葉士芃

China Medical University Hospital

Division of Hematology & Oncology

Search Result

List